28.78 -41.92 (-152.21%)
BDX
Stock Details
Last Trade:28.78 Change:-41.92 (-152.21%) Prev Close:70.70 Open: 27.54 Days Range:25.00 – 29.98 52 Week Range: 58.14 - 89.24 Volume:441154 P/E: 6.23EPS:4.62
View AllRecent Alerts 07/04/09
Recent Alert on 06/12/09 at 9:45am
Notable Analyst Rating Changes 6/12: SKS, CSX, SNIC, PBR Upgraded; AKS, ERIC, TWTC, HGSI Downgraded
Notable Analyst Rating Changes 6/12: SKS, CSX, SNIC, PBR Upgraded; AKS, ERIC, TWTC, HGSI Downgraded
UPGRADES: Deutsche Bank upgrades Saks (NYSE: SKS) from Hold to Buy and a Street High $7 price target. Click here for more color on the upgrade. Morgan Stanley upgrades CSX (NYSE: CSX) from Equal Weight to Overweight with a $52 price target,... Read More
Recent Alert on 06/12/09 at 8:58am
ThinkEquity Initiates Coverage on Becton, Dickinson (BDX) with a Buy
ThinkEquity Initiates Coverage on Becton, Dickinson (BDX) with a Buy
Recent Alert on 05/20/09 at 8:39am
Becton, Dickinson and Company (BDX) Declares Quarterly Dividend of $0.33, Yielding 2.04%
Becton, Dickinson and Company (BDX) Declares Quarterly Dividend of $0.33, Yielding 2.04%
Recent Alert on 05/04/09 at 8:56am
Becton, Dickinson (BDX) and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection
Becton, Dickinson (BDX) and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection
Recent Alert on 05/04/09 at 8:56am
Becton, Dickinson (BDX) and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection
Becton, Dickinson (BDX) and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection
View AllRecent Press Releases
No Recent Press Releases Available